Search results for "Intestinal"

showing 10 items of 2024 documents

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

2017

Background: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle. However, it has a relevant toxicity profile that mainly occurs within the first cycles of therapy, and dose and schedule adjustments are often required to reduce the frequency or severity of adverse events and to avoid early treatment discontinuation. To date, large amounts of data on the use of REG in metastatic GIST patients in daily clinical practice are not available, and we lack information about how this treatment personalization really a…

0301 basic medicineOncologymedicine.medical_specialtyScheduleStromal cellSettore MED/06 - Oncologia Medicalcsh:RC254-282PersonalizationNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicinetyrosine kinase inhibitorQuality of lifeInternal medicineRegorafenibtyrosine kinase inhibitorsmedicineOriginal Researchreferral centresGiSTbusiness.industryGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitors; OncologyGastrointestinal stromal tumourslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenspersonalized treatmentClinical PracticeGIST; personalized treatment; quality of life; referral centres; regorafenib; tyrosine kinase inhibitorsreferral centre030104 developmental biologychemistryquality of lifeOncology030220 oncology & carcinogenesisregorafenibbusinessGIST personalized treatment quality of life referral centres regorafenib tyrosine kinase inhibitorsGIST
researchProduct

A catch-22: Interleukin-22 and cancer.

2017

Barrier surfaces of multicellular organisms are in constant contact with the environment and infractions to the integrity of epithelial surfaces is likely a frequent event. Interestingly, components of the immune system, that can be activated by environmental compounds such as the microbiota or nutrients, are interspersed among epithelial cells or directly underlie the epithelium. It is now appreciated that immune cells continuously receive and integrate signals from the environment. Curiously, such continuous reception of stimulation does not normally trigger an inflammatory response but mediators produced by immune cells in response to such signals seem to rather promote barrier integrity…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentImmunologyBiologyPolymorphism Single NucleotideEpitheliumMalignant transformationTight JunctionsInterleukin 2203 medical and health sciences0302 clinical medicineImmune systemInternal medicineNeoplasmsmedicineImmunology and AllergyAnimalsHumansLymphocytesIntestinal MucosaReceptorWound HealingInterleukinsMicrobiotaInnate lymphoid cellEpithelial CellsEpitheliumImmunity InnateCell biology030104 developmental biologyCytokinemedicine.anatomical_structureCell Transformation NeoplasticWound healing030215 immunologyEuropean journal of immunology
researchProduct

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

Intestinal dysbiosis and innate immune responses in axial spondyloarthritis

2016

Purpose of review Inflammatory innate and adaptive immune cell responses to commensal bacteria underlie the pathogenesis of human chronic inflammatory diseases. Intestinal dysbiosis has been described in patients with spondyloarthritis (SpA) and seems to be correlated with histologic and immunologic alterations. Purpose of this review is to discuss the relationship occurring between intestinal dysbiosis and innate immune responses in patients with axial SpA. Recent findings Intestinal dysbiosis and differential activation of intestinal immune responses in patients with SpA have been demonstrated. Furthermore, innate cells that appear to be involved in the pathogenesis of SpA may control int…

0301 basic medicinePathogenesis03 medical and health sciences0302 clinical medicineImmune systemRheumatologyImmunityIL-23dysbiosis; gut inflammation; IL-17; IL-23; IL-9; innate lymphoid cells; spondyloarthritis; RheumatologySpondylarthritisInterleukin 23MedicineHumansspondyloarthriti030203 arthritis & rheumatologyInnate immune systemBacteriabusiness.industrydysbiosiInnate lymphoid cellmedicine.diseaseIL-9Immunity InnateGastrointestinal MicrobiomeIntestinesIL-17030104 developmental biologyImmunologyinnate lymphoid cellDysbiosisInterleukin 17gut inflammationbusinessDysbiosis
researchProduct

Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report

2020

Plasmablastic lymphoma is a rare subtype of non-Hodgkin’s lymphoma, which generally presents an aggressive clinical course and low survival rates. It is strongly associated with HIV infection and the most common site of involvement of the territory of the head and neck is Waldeyer’s lymphatic ring, followed by the gastrointestinal tract, lymph nodes and skin. The morphological characteristics of PBL in the oral cavity / jaw in the context of HIV infection show diffuse sheets of large immunoblastic cells with abundant cytoplasm, vesicular chromatin and prominent nucleus, a small located in the center with plasma cells differentiation. The main goal of this article is to review the literature…

0301 basic medicinePathologymedicine.medical_specialtyHuman immunodeficiency virus (HIV)Case ReportContext (language use)medicine.disease_cause03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)immune system diseaseshemic and lymphatic diseasesmedicineGeneral DentistryGastrointestinal tractOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseLymphoma030104 developmental biologyLymphatic system030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASLymphbusinessPlasmablastic lymphomaJournal of Clinical and Experimental Dentistry
researchProduct

Two-year-old girl with tuberous xanthomas.

2018

A 2-year-old girl was referred for evaluation because she had two nodular lesions located on both heels, and another elongated lesion in the intergluteal cleft. On physical examination, two yellow to orange well-defined nodules, suggestive of xanthomas, were bilaterally located on the Achilles tendon areas (figure 1A). Moreover, another yellowish, slightly raised lesion with band-like morphology was seen in the intergluteal cleft (figure 1B). There were no other anomalies on physical examination. Figure 1 (A) Tuberous xanthoma located on the left heel. (B) Planar xanthoma located in the intergluteal cleft. (C) Peripheral blood smear examination showing numerous red cells and two macrothromb…

0301 basic medicinePathologymedicine.medical_specialtyIntergluteal cleftHypercholesterolemiaPhysical examination030204 cardiovascular system & hematologyXanthomaHigh cholesterolLipid Metabolism Inborn ErrorsPathology and Forensic MedicineLesion03 medical and health sciences0302 clinical medicineBiopsymedicineXanthomatosisHumansAchilles tendonmedicine.diagnostic_testbusiness.industryATP Binding Cassette Transporter Subfamily G Member 8PhytosterolsGeneral Medicinemedicine.diseaseIntestinal Diseases030104 developmental biologymedicine.anatomical_structureChild PreschoolMutationFemalemedicine.symptomLipid profilebusinessJournal of clinical pathology
researchProduct

Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology

2018

Pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare subtype of lung adenocarcinoma recently recognized in the WHO classification. It is defined as an adenocarcinoma in which the enteric component exceeds 50% and have to show the expression of at least 1 immunohistochemical marker of enteric differentiation. Although the definition of this tumor type is very important, above all in the differential diagnosis between a primary lung tumor and a metastasis of colorectal adenocarcinoma, this cancer still lacks a distinctive immunohistochemical and molecular signature. We recruited the largest series in the literature of PAEDs according to the morphology and the positivity for …

0301 basic medicinePathologymedicine.medical_specialtyLung NeoplasmsHistologyintestinal-type adenocarcinomaCellular differentiationDNA Mutational AnalysisThyroid Nuclear Factor 1AdenocarcinomaBiologymedicine.disease_causePathology and Forensic MedicineMetastasisDiagnosis DifferentialProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineKRASBiomarkers TumormedicineHumansCDX2 Transcription FactorPathology Molecularenteric lung adenocarcinoma intestinal-type adenocarcinoma CDX-2 CDX2 KRASLungKeratin-7entericCancerCell DifferentiationPulmonary adenocarcinoma with enteric differentiation (PAED)lung adenocarcinomamedicine.diseaseCDX-2ImmunohistochemistryMedical Laboratory Technology030104 developmental biologymedicine.anatomical_structureCDX2Alveolar Epithelial Cells030220 oncology & carcinogenesisMutationAdenocarcinomaImmunohistochemistryKRASDifferential diagnosisColorectal Neoplasms
researchProduct

Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis

2018

The commensal gut microbiota is an environmental factor that has been implicated in the development of cardiovascular disease. The development of atherosclerotic lesions is largely influenced not only by the microbial-associated molecular patterns of the gut microbiota but also by the meta-organismal trimethylamine N-oxide pathway. Recent studies have described a role for the gut microbiota in platelet activation and arterial thrombosis. This review summarizes the results from gnotobiotic mouse models and clinical data that linked microbiota-induced pattern recognition receptor signalling with atherogenesis. Based on recent insights, we here provide an overview of how the gut microbiota cou…

0301 basic medicinePharmacologybiologybusiness.industryGastrointestinal MicrobiomePattern recognition receptorDiseaseGut florabiology.organism_classificationmedicine.diseasedigestive systemThrombosis03 medical and health sciences030104 developmental biologyImmunologyMedicinePlatelet activationMicrobiomebusinessBritish Journal of Pharmacology
researchProduct

Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer

2018

Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-ta…

0301 basic medicinePhysiologyCytotoxicityCancer Treatmentlcsh:MedicineNK cellsToxicologyPathology and Laboratory MedicineAntineoplastic Agents ImmunologicalSpectrum Analysis Techniques0302 clinical medicineImmune PhysiologyCellular typeslcsh:ScienceInnate Immune SystemCytotoxicity AssayMultidisciplinarybiologyChemistryImmune cellsCD137Drug SynergismFlow CytometryRecombinant ProteinsUp-RegulationGene Expression Regulation NeoplasticKiller Cells NaturalOncologySpectrophotometry030220 oncology & carcinogenesisCytokinesWhite blood cellsFemaleTumor necrosis factor alphaCytophotometryAntibodyResearch ArticleCell biologyBlood cellsCell Survivalmedicine.drug_classImmunologyAntibodies Monoclonal HumanizedResearch and Analysis MethodsMonoclonal antibody03 medical and health sciencesImmune systemStomach NeoplasmsCell Line TumorGastrointestinal TumorsmedicineHumansSecretionCell ProliferationMedicine and health sciencesBiology and life scienceslcsh:RCancers and NeoplasmsCancerTrastuzumabMolecular Developmentmedicine.diseaseGranzyme BGastric Cancer4-1BB Ligand030104 developmental biologyAnimal cellsImmune SystemCancer cellCancer researchbiology.proteinlcsh:QPhysiological ProcessesDevelopmental BiologyPLOS ONE
researchProduct

Life history adjustments to intestinal inflammation in a gut nematode.

2017

ABSTRACT Many parasitic nematodes establish chronic infections. This implies a finely tuned interaction with the host immune response in order to avoid infection clearance. Although a number of immune interference mechanisms have been described in nematodes, how parasites adapt to the immune environment provided by their hosts remains largely unexplored. Here, we used the gastrointestinal nematode Heligmosomoides polygyrus to investigate the plasticity of life history traits and immunomodulatory mechanisms in response to intestinal inflammation. We adopted an experimental model of induced colitis and exposed worms to intestinal inflammation at two different developmental stages (larvae and …

0301 basic medicinePhysiologyPhenotypic plasticityAquatic ScienceHost-Parasite InteractionsImmunomodulation03 medical and health sciencesMice0302 clinical medicineImmune systemparasitic diseases[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/Symbiosismedicine[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyAnimalsColitisAdaptationIntestinal Diseases ParasiticMolecular BiologyLife History TraitsEcology Evolution Behavior and SystematicsStrongylida InfectionsInfectivityInflammationStrongyloideaPhenotypic plasticityMice Inbred BALB CbiologyHost (biology)Dextran SulfateInflammatory responseHelminth Proteinsmedicine.diseasebiology.organism_classification3. Good healthIntestinesDisease Models Animal030104 developmental biologyNematodeInfectivityInsect ScienceLarvaImmunology[SDV.IMM]Life Sciences [q-bio]/ImmunologyAnimal Science and ZoologyHeligmosomoides polygyrusAdaptation030215 immunology[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/SymbiosisThe Journal of experimental biology
researchProduct